2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 113

A Primer on Exercise: An Interactive, Online Educational Module Incorporating Spaced Education to Supplement the ACR Core Curriculum Outline for Rheumatology Fellowship Programs

Education Poster

9:00AM-11:00AM: Abstract Number: 112

A Qualitative Assessment of a CME “City Rounds” Workshop Educational Program to Meet the Educational Needs of Rheumatologists

Education Poster

9:00AM-11:00AM: Abstract Number: 318

A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 373

a Retrospective Study of Clinical Factors Influencing the Development of Overlapping Disease Features in Pediatric Patients with Chronic Recurrent Multifocal Osteomyelitis (CRMO) and Spondyloarthropathies (SpA)

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Autoinflammatory Disorders and Miscellaneous

9:00AM-11:00AM: Abstract Number: 157

A Systematic Review of the Upper Limb Soft Tissue Comorbidities in Patients with Type 2 Diabetes Mellitus

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

9:00AM-11:00AM: Abstract Number: 59

Abaloparatide, a Novel PTHrP Analog, Increased Bone Mass and Density at Cortical and Trabecular Sites in an Orchiectomized Rat Model of Male Osteoporosis

Biology and Pathology of Bone and Joint Poster I

9:00AM-11:00AM: Abstract Number: 419

Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 680

Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 14

Abnormalities in Th1, Th2 and Th17 Lymphoid Subpopulations in Long-Term Evolution Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 462

ABP 710: Matching Critical Biological Functions with Infliximab

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 57

Accelerated Development of Aging-Associated and Instability-Induced Osteoarthritis in 12/15-Lipoxygenase Deficient Mice

Biology and Pathology of Bone and Joint Poster I

9:00AM-11:00AM: Abstract Number: 340

Accessing Positive (but Not Negative) Online Reviews Is Associated with Increased Willingness to Take Medication

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 799

Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 432

ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 578

Added Value of Biomarkers Compared to Routine Clinical Parameters for the Prediction of Radiographic Spinal Progression in Axial Spondyloarthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].